E-ISSN: 2619-9467

Contents    Cover    Publication Date: 19 Dec 2019
Year 2019 - Volume 29 - Issue 4

Open Access

Peer Reviewed

ORIGINAL RESEARCH
2206 Viewed942 Downloaded

Comparison of the Immunohistochemical Expression of Caveolin-1 in Endometrial Carcinoma, Endometrial Intraepithelial Neoplasia, Endometrial Hyperplasia, and Normal Endometrium

Full Text PDF  
J Clin Obstet Gynecol. 2019;29(4):123-8
DOI: 10.5336/jcog.2019-71119
Article Language: EN
Copyright Ⓒ 2020 by Türkiye Klinikleri. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
ABSTRACT
Objective: This retrospective study was designed to evaluate the importance of tissue expressions of caveolin-1 (Cav-1) known as signal regulator in differential diagnosis of endometrial lesions. Material and Methods: A total of 65 patients with normal endometrium (11 proliferative and 10 secretory epithelium, 32.3%), endometrial hyperplasia without atypia (EH) (n=11, 16.9%); atypical endometrial hyperplasia/ endometrioid intraepithelial neoplasia (AEH/EIN) (n=11; 16.9%) and endometrial carcinoma (EC) (n=22; 33.8%) were recruited for the study. Sections prepared from biopsy materials or hysterectomy specimens of the patients were immunohistochemically processed, stained, and examined for the presence of caveolin-1 expression. The positive association between immunohistochemical staining of caveolin-1 and its relationship with characteristic features of lesions and age of the patients were investigated. Results: The mean age of the patients was 49.1± 8.5 years. Stromal fibroblasts were positively stained for Cav-1 in 26 (40%) cases, and stromal expressions of Cav-1. Stromal Cav-1 expressions were detected in indicated cases with EH (36.4%), EIM (27.3%), and EC (68.2%), while only in 19% of normal endometrial biopsy specimens. It was determined that if the tumor becomes more invasive, then its stromal Cav-1 expression reaches to statistically significantly higher levels (p=0.001). Conclusion: Our findings demonstrated that stromal Cav-1 expression could be used as a marker for malignancy and invasiveness of endometrial neoplasms.
REFERENCES:
  1. Lisanti MP, Scherer PE, Tang Z, Sargiacomo M. Caveolae, caveolin and caveolin-rich membrane domains: a signaling hypothesis. Trends Cell Biol. 1994;4(7):231-5. [Crossref] [PubMed]
  2. Hurlstone AF, Reid G, Reeves JR, Fraser J, Strathdee G, Rahilly M, et al. Analysis of the Caveolin-1 gene at human chromosome 7q31.1 in primary tumors and tumor-derived cell lines. Oncogene. 1999;18(10):1881-90. [Crossref] [PubMed]
  3. Razani B, Woodman SE, Lisanti MP. Caveolae: from cell biology to animal physiology. Pharmacol Rev. 2002;54(3):431-67. [Crossref] [PubMed]
  4. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6(5):392-401. [Crossref] [PubMed]
  5. Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol. 2009;174(6):2023-34. [Crossref] [PubMed] [PMC]
  6. Huang CF, Yu GT, Wang WM, Liu B, Sun ZJ. Prognostic and predictive values of SPP1, PAI and caveolin-1 in patients with oral squamous cell carcinoma. Int J Clin Exp Pathol. 2014;7(9):6032-9. [PubMed]
  7. Chatterjee M, Ben-Josef E, Thomas DG, Morgan MA, Zalupski MM, Khan G, et al. Caveolin-1 is associated with tumor progression and confers a multi-modality resistance phenotype in pancreatic cancer. Sci Rep. 2015;5:10867. [Crossref] [PubMed] [PMC]
  8. Sayhan S, Diniz G, Karadeniz T, Ayaz D, Kahraman DS, Gokcu M, et al. Expression of caveolin-1 in peritumoral stroma is associated histological grade in ovarian serous tumors. Ginekol Pol. 2015;6(6):424-8. [Crossref] [PubMed]
  9. Eliyatkin N, Aktas S, Diniz G, Ozgur HH, Ekin ZY, Kupelioglu A. Expression of stromal Caveolin- 1 may be a predictor for aggressive behaviour of breast cancer. Pathol Oncol Res. 2018;24(1):59-65. [Crossref] [PubMed]
  10. Aydın HA, Bayramoğlu Z, Erdoğan G, Peştereli E, Şimşek T. Comparison oft he immunohistochemical staining of lumican in endometrioid-type endometrial cancer and endometrial intraepithelial neoplasias. JCOG. 2019;29(2):50-6. [Crossref]
  11. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009;16(1):8-13. [Crossref] [PubMed]
  12. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of tumours of female reproductive organs. In: Zaino R, Carinelli SG, Ellenson LH, Eng G, Karabuchi H, Kanishi I, eds. Epithelial Tumours and Precursors. 4th ed. France: IARC; 2014. p.125-35.
  13. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: Gynecologic Oncology Group study. Cancer. 2006;106(4):812-9. [Crossref] [PubMed]
  14. Diaz-Valdivia N, Bravo D, Huerta H, Henriquez S, Gabler F, Vega M, et al. Enhanced caveoli-1 expression increases migration, anchorage-independent growth and invasion of endometrial adenocarcinoma cells. BMC Cancer. 2015;15(463):1-11. [Crossref] [PubMed] [PMC]
  15. Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene. 1998;16(11):1391-7. [Crossref] [PubMed]
  16. Bender FC, Reymond MA, Bron C, Quest AF. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res. 2000;60(20):5870-8. [PubMed]
  17. Fiucci G, Ravid D, Reich R, Liscovitch M. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene. 2002;21(15):2365-75. [Crossref] [PubMed]
  18. Quest AF, Leyton L, Párraga M. Caveolins, caveolae, and lipid rafts in cellular transport, signaling, and disease. Biochem Cell Biol. 2004;82(1):129-44. [Crossref] [PubMed]
  19. Nú-ez-Wehinger S, Ortiz RJ, Díaz N, Díaz J, Lobos-González L, Quest AF. Caveolin-1 in cell migration and metastasis. Curr Mol Med. 2014;14(2):255-74. [Crossref] [PubMed]
  20. Ayala G, Morello M, Frolov A, You S, Li R, Rosati F, et al. Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression. J Pathol. 2013;231(1):77-87. [Crossref] [PubMed] [PMC]
  21. Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res. 2002;62(11):3298-307. [PubMed]
  22. Campbell L, Gumbleton M, Griffiths DF. Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br J Cancer. 2003;89(10):1909-13. [Crossref] [PubMed] [PMC]
  23. Paskaš S, Janković J, Marečko I, Išić Denčić T, Tatić S, Cvejić D, et al. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status. Otolaryngol Head Neck Surg. 2014;150(2):201-9. [Crossref] [PubMed]
  24. Senetta R, Stella G, Pozzi E, Sturli N, Massi D, Cassoni P. Caveolin-1 as a promoter of tumour spreading: when, how, where and why. J Cell Mol Med. 2013;17(3):325-36. [Crossref] [PubMed] [PMC]
  25. Goetz JG, Minguet S, Navarro-Lérida I, Lazcano JJ, Samaniego R, Calvo E, et al. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell. 2011;146(1):148-63. [Crossref] [PubMed] [PMC]
  26. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006;24(29):4783-91. [Crossref] [PubMed] [PMC]